WO2006067967A1 - Préparation liquide pour cavité orale - Google Patents

Préparation liquide pour cavité orale Download PDF

Info

Publication number
WO2006067967A1
WO2006067967A1 PCT/JP2005/022449 JP2005022449W WO2006067967A1 WO 2006067967 A1 WO2006067967 A1 WO 2006067967A1 JP 2005022449 W JP2005022449 W JP 2005022449W WO 2006067967 A1 WO2006067967 A1 WO 2006067967A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
amount
mass
moles
liquid oral
Prior art date
Application number
PCT/JP2005/022449
Other languages
English (en)
Japanese (ja)
Inventor
Kazuo Mukasa
Eiji Nishinaga
Yasuo Nomura
Hideaki Kanno
Original Assignee
Lion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corporation filed Critical Lion Corporation
Priority to JP2006548784A priority Critical patent/JP4873154B2/ja
Publication of WO2006067967A1 publication Critical patent/WO2006067967A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to a liquid oral composition that exhibits bactericidal power against airborne bacteria, exhibits osmotic bactericidal power against biofilms, and has good appearance stability of the composition.
  • liquid oral compositions particularly when an insoluble thione fungicide with high oil solubility is combined, it hardly dissolves in water as it is, so various surfactants are used for solubilization. Formulated and solubilized. For this reason, the active site of the bactericidal agent is inactivated by the surfactant, so that the bactericidal power cannot be sufficiently exerted, and if the blending amount of the surfactant is reduced to improve the bactericidal power, the liquid becomes clouded over time. There was a problem that the appearance stability of the composition was significantly impaired. Therefore, it has been desired to develop a liquid oral composition having good appearance stability even during long-term storage while exerting sterilizing power.
  • An object of the present invention is to provide a liquid oral composition that exerts bactericidal power against airborne bacteria, exhibits osmotic bactericidal power against biofilms, and has good appearance stability.
  • the present inventors have identified a liquid oral composition using isopropylmethylphenol and triclosan as a bactericidal component as a nonionic surfactant.
  • a liquid oral composition using isopropylmethylphenol and triclosan as a bactericidal component as a nonionic surfactant.
  • polyoxyethylene hydrogenated castor oil and / or polyoxyethylene alkyl ether When blended with polyoxyethylene hydrogenated castor oil and / or polyoxyethylene alkyl ether, it exhibits bactericidal power against airborne bacteria, exhibits excellent penetrating and bactericidal power against nokifolm, and ethanol. It has been found that when blended, a liquid oral composition having good appearance stability can be obtained even when stored at high temperatures.
  • the present invention provides:
  • a liquid oral composition is provided.
  • the liquid oral composition of the present invention exhibits bactericidal power against airborne bacteria, exhibits osmotic sterilizing power against biofilms, and has good appearance stability.
  • the liquid oral composition of the present invention comprises (A) isopropylmethylphenol and (B) triclosan as bactericidal components, and (C) a specific polyoxyethylene hydrogenated castor oil and / or nonionic surfactant. Alternatively, it is characterized by containing polyoxyethylene alkyl ether and (D) ethanol.
  • the amount of component (A) isopropylmethylphenol used in the present invention is 0.01 to 0.1% (mass%, The same applies hereinafter), particularly in terms of bactericidal power and appearance stability, it is preferable to be 0.02 to 0.08%, and if it is less than 0.01%, the bactericidal power may not be exerted on the biofilm, 0. If it exceeds 1%, it becomes cloudy, and appearance stability may be impaired during storage at high and low temperatures.
  • the amount of the component (B) triclosan used in the present invention is 0.01 to 0.1% of the total composition, particularly in terms of bactericidal activity, in terms of exerting osmotic fungicide on the biofilm. In terms of appearance stability, it should be 0.02-0.08% S. If it is less than 0.01%, the sterilizing power may not be able to be exerted against the quino-finolem. If it exceeds 1%, it may become cloudy and the appearance stability may be impaired during storage at high and low temperatures.
  • the present invention requires the combined use of isopropylmethylphenol and triclosan as described above, and when isopropylmethylphenol or triclosan is used alone, sterilization is excellent against both floating bacteria and biofilms. An effect cannot be given.
  • the nonionic surfactant of component (C) used in the present invention includes polyoxyethylene hydrogenated castor oil having an average number of moles of ethylene oxide added of 40 to 100 moles, and Z or carbon chain length. Is a polyoxyethylene alkyl ether having an alkyl chain length of 16 to 18 and an average addition mole number of ethylene oxide of 10 to 40 mol.
  • Polyoxyethylene hydrogenated castor oil with an average addition mole number of lenoxide of 60 to 100 moles, a polyoxyethylene alkyl having an alkyl chain length of 16 to 18 and an average addition mole number of ethylene oxide of 20 to 40 moles I prefer ether.
  • Polyoxyethylene hydrogenated castor oil with an average added mole number of ethylene oxide of less than 40 moles may precipitate during low-temperature storage, and those with more than 100 moles are generally not commercially available.
  • the average number of moles of polyoxyethylene alkyl ether added is less than 10 moles, precipitation may occur during storage at low temperatures, and those exceeding 40 moles are generally not commercially available. If the alkyl chain length is less than 16, bitterness and irritation may be strong, and those exceeding 18 may have poor appearance stability during low-temperature storage.
  • the blending amount is 0.1 to 2%, particularly 0.2 to 1% of the total composition in terms of solubilization of isopropylmethylphenol and triclosan and improvement in appearance stability. If it is less than 0.1%, it is difficult to maintain the appearance stability during storage at high and low temperatures. If it exceeds 2%, the biofilm may not be sterilized.
  • the blending amount of the component (D) ethanol used in the present invention is preferably 3 to 20%, particularly 5 to 15% from the viewpoint of improving the appearance stability at high temperature storage. If it is less than%, it may be difficult to maintain the appearance stability, and if it exceeds 20%, the irritation may be strong and the usability may be significantly impaired.
  • sodium lauryl sulfate can be added to the liquid oral composition of the present invention for the purpose of improving the osmotic sterilizing power of isopropylmethylphenol and triclosan.
  • the blending amount is preferably 0.05 to 1% of the whole composition, particularly 0.1 to 0.5%, and if it is less than 0.05%, the effect of adding osmotic sterilization power to the biofilm is increased. If it exceeds 1%, the taste of the liquid oral composition may be seriously impaired.
  • the liquid oral composition of the present invention may contain one or more of xylitol, cinnamic aldehyde, orange oil, and vanetol for the purpose of alleviating the bitterness derived from the bactericidal agent.
  • the xylitol content is preferably 0.:! To 10%, especially 1 to 7% of the total composition. Less than 0.1% has little effect on alleviating the bitterness derived from fungicides. If it exceeds 10%, the effect may be saturated.
  • the total amount of cinnamic aldehyde should be 0.0001 to 0.05%, especially 0.0005 to 0.01% of the total yarn and composition.
  • the effect of alleviating the bitterness derived from the fungicide is small. If it exceeds 0.05%, the effect may be saturated.
  • the amount of orange oil should be 0.0005 to 0.05% of the total composition, especially 0.001 to 0.01%, and if it is less than 0.005%, the bitterness derived from the fungicide The effect of alleviating is too small. If it exceeds 0.05%, the effect may be saturated.
  • the amount of anethole is preferably 0.0005-0.05%, particularly 0.001 to 0.01% of the total composition, and less than 0.055% reduces the bitterness derived from the fungicide. The effect is small. If it exceeds 0.05%, the effect may be saturated.
  • the liquid oral composition of the present invention can be prepared and applied as a rinsing lj, a mouth freshener, a concentrated mouthwash, etc., but the liquid oral composition of the present invention includes In addition to the above-mentioned components, any appropriate component can be blended depending on the dosage form, such as a wetting agent, a thickener, a PH adjusting agent, a preservative, a sweetener, a fragrance, a surfactant, an active ingredient, Coloring agents can be added.
  • the wetting agent Sonolebithonole, propylene glycol, ethylene glycol, polyethylene glycol, maltite, lactit and the like can be blended.
  • the blending amount is preferably 1 to 5% of the entire composition.
  • xanthan gum xanthan gum, carrageenan, hydroxyethyl cellulose, carboxymethyl cellulose, sodium alginate, polybutyl alcohol and the like can be blended.
  • the blending amount is preferably 0.01 to 0.5% of the entire composition.
  • Examples of the preservative include sodium benzoate, methylparaben, ethylparaben, propylparaben, butylparaben, cetylpyridinium chloride, potassium sorbate and the like.
  • saccharin sodium As the sweetening agent, saccharin sodium, stevioside and the like can be blended.
  • Perfumes other than those mentioned above include peppermint oil, spearmint oil, eucalyptus oil, winter green oil, clove oil, thyme oil, sage oil, force nodamon oil, rosemary oil, marjoram oil, lemon oil, nutmeg Oil, natural essential oils such as lavender oil, paracres oil, and 1_ menthol, 1 struggle rubon, 1,8-cineole, methyl salicylate, eugenol, timo Fragrance components contained in the above natural essential oils such as cornol, linalool, limonene, menthone, menthyl acetate, citral, camphor, borneol, binene, spirantol, etc., ethinoreacetate, ethinolevbutyrate, isoaminole Acetate, hexana monole, hexenal, methyl anthranilate, ethyl methyl phenyl daricidate, benzal
  • Surfactants other than those mentioned above include sodium myristyl sulfate, N lauroyl zanolecosinate, lauroyl methyl taurine, isyl amino acid salt, sodium dodecylbenzenesulfonate, sodium sulfofatty acid alkyl ester 'sodium, alkyl phosphate ester
  • Anionic surfactants such as salt, betaine acetate type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine, fatty acid amidopyl dimethyldimethylaminoacetic acid betaine, N-fatty acid acidoley N-canoleboxoxymethinole N-hydroxyethynoleethylene diamine salt and other imidazoline type amphoteric surfactants, N-fatty acid acyl-L-alginate salt and other amino acid type surfactants can be used alone or in combination. The amount can be used as 0-5%.
  • anti-inflammatory agents such as tranexamic acid, epsilon-amino-proic acid, dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, ritechenzy Enzymes such as sodium fluoride, fluorides such as sodium monofluoride, sodium monofluorophosphate, stannous fluoride, vitamin C such as aluminum chlorohydroxy allantoin, allantoin, azulene, lysozyme chloride, ascorbic acid, dihydrocholesterol, glycyrrhetin Plant extracts such as salts, glycyrrhetinic acids, hydrocholesterol, chlorofinole, copper chlorophyllin sodium, thyme, gon, chiioji, hamamelis, Copper dalconate, caropeptide, sodium polyphosphate, water-soluble in
  • a highly safe water-soluble pigment such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105, and the like can be added.
  • pH adjusters include phthalic acid, phosphoric acid, citrate, succinic acid, acetic acid, fumaric acid, malic acid and carbonic acid and their potassium, sodium and ammonium salts, ribonucleic acid and its salts, and water.
  • One kind or two or more kinds such as sodium oxide can be used, and in particular, a combination of phosphoric acid, citrate and a sodium salt thereof is preferable.
  • the liquid oral composition of the present invention preferably adjusts the pH at 25 ° C. to 5.5 to 8.5 as a pH adjusting agent in the vicinity thereof.
  • Sodium hydrogen or a combination of citrate and sodium citrate can be used.
  • PET polyethylene terephthalate
  • glass polypropylene
  • polyethylene polyethylene
  • liquid oral compositions were prepared using isopropylmethylphenol (Osaka Kasei), triclosan (Ciba 'Specialty' Chemicals), polyoxyethylene (60) hydrogenated castor oil (Nikko Chemicals), Lioxyethylene (30) cetyl ether (manufactured by Nippon Emulsion), ethanol (manufactured by Nippon Alcohol), sodium lauryl sulfate (manufactured by Toho Chemical), citrate (manufactured by Fuso Chemical), sodium citrate (manufactured by Fuso Chemical), Xylitol (made by Rocket Fleure) Synthetic Aldehyde (brand name made by Cynamic aldehyde Eizo Main Store), orange oil (brand name made by Orange Calabria LD—294 Taiyo Fragrance), Anethole (brand name
  • % means “mass%” unless otherwise specified, and “part” means “mass part”.
  • pH in the table was measured using a pH meter (Model No. HM-3 OS) manufactured by Toa Denpa Kogyo immediately after adjustment, and the value after 3 minutes at 25 ° C was shown.
  • Bacterial solution used was 30g Trypticase Soy Broth (Difco) dissolved in 1L of purified water as a culture solution, and Actinomyces naesrandi ATCC 51655 was used as an oral resident bacterium at 37 ° C.
  • the physiological saline solution was prepared so that the permeability at 550 nm of the liquid cultured for 1 day under anaerobic conditions (5% carbon dioxide, 95% nitrogen) was 20.
  • Sampnore shown in Table 1, Table 2 and Table 3. Add 0.3 mL of bacterial solution to 7 mL, stir, react at 37 ° C for 1 minute, stir again, and add 2.7 mL of culture solution in advance.
  • test tubes Five test tubes were prepared, and 0.3 mL was added to the first test tube and stirred. 0.3 mL of this solution was collected and added to a second test tube and stirred. This operation was similarly performed in order on test tubes 3-5.
  • Viable count is less than 10 3
  • Viable count is 10 3 or more and less than 10 4
  • HA plate made by Asahi Optical Co., Ltd. 7 mm in diameter and 3.5 mm in thickness (Asahi Optical Co., Ltd.) treated with human unstimulated saliva filtered through a 0.45 am filter as a carrier for preparing model plaque
  • trypticase soy broth Difco
  • hemin Sigma
  • menadione Sigma
  • Streptococcus gordonii ATCC51656 strain and Actinomyces naeslandi ATCC516 as oral resident bacteria to produce model plaque 55 strains and Borfiromonas gingivalis ATCC33277 strain were used as pathogenic bacteria.
  • These three bacterial species are inoculated into the above culture solution to 2 x 10 7 cfu / mL (cfu: colony forming units), respectively, together with saliva-treated HA carrier at 37 ° C under anaerobic conditions (5% carbonate Gas, 95% nitrogen) was continuously cultured for 2 weeks (the replacement rate of the culture medium was set to 10 Vol%) to form model plaques mixed with three bacterial species on the HA surface.
  • model plaque was immersed in 2 mL of the sample shown in Table 1, Table 2 and Table 3 for 3 minutes and washed 6 times with 1 mL of sterile physiological saline. Then, model plaques are dispersed by ultrasonic treatment (200 ⁇ , 10 seconds) with 4 mL of sterilized physiological saline, a triptychose soy agar plate (made by Dif co) containing 10% sheep defibrillating blood, and kanamycin sulfate (200 mg). (/ L: Sigma Co.) containing tripty case soy blood agar plate was smeared 50 / L and cultured under anaerobic conditions. The grown colonies were counted, and the number of remaining B. gingivalis bacteria (cfu) was determined and determined according to the following criteria.
  • Viable count is less than 10 6
  • Viable count is 10 6 or more and less than 10 7
  • Viable count is 10 7 or more and less than 10 8
  • Cis 3 Hexenore 1 part Trans 2—Hexena 1 part 1 part ⁇ ⁇ ⁇ Butylate 1 part Undecalataton 1 part Decalataton 1 part Isoamilacetate 1 part Benzaldehyde 1 part Hexyl / Reacetate 1 part —Methylbutyrate 1 part Benzyl / Rare / Reco 1 / Le 1 part ⁇ Terpineol 1 part Linalyl acetate 1 part Phenylethyl glycidate 1 part Phenylethyl alcohol 1 part Carylhexanoate 1 part Octanol 1 part Methyl cinnamate 1 part Methinoleheptinoloneponate 1 part Honon 1 part Ethyl ⁇ -methylthiopropionate 1 part Cis 6-Nonenol 1 part Carrone 1 part Methinoregius monone 1 part Ethanol 1 part

Abstract

La présente invention décrit une préparation liquide pour cavité orale caractérisée en ce qu'elle comprend (A) de l’isopropylméthylphénol, (B) du triclosan, (C) de l'huile de ricin hydrogénée contenant du polyoxyéthylène où le nombre de moles d'oxyde d'éthylène ajouté est compris entre 40 et 100, et/ou un alkyléther contenant du polyoxyéthylène et dont la chaîne alkyle est en C16-C18, et où le nombre moyen de moles d'oxyde d'éthylène ajouté est compris entre 10 et 40, et (D) de l'éthanol. La préparation liquide pour cavité orale présente une activité fongicide contre les champignons flottants ainsi qu’une activité fongicide systémique contre les films biologiques, tout en conservant une apparence satisfaisante et stable.
PCT/JP2005/022449 2004-12-24 2005-12-07 Préparation liquide pour cavité orale WO2006067967A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006548784A JP4873154B2 (ja) 2004-12-24 2005-12-07 液体口腔用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-374924 2004-12-24
JP2004374924 2004-12-24

Publications (1)

Publication Number Publication Date
WO2006067967A1 true WO2006067967A1 (fr) 2006-06-29

Family

ID=36601570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/022449 WO2006067967A1 (fr) 2004-12-24 2005-12-07 Préparation liquide pour cavité orale

Country Status (2)

Country Link
JP (1) JP4873154B2 (fr)
WO (1) WO2006067967A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008100964A (ja) * 2006-10-20 2008-05-01 Kao Corp バイオフィルム生成抑制剤組成物
JP2008150305A (ja) * 2006-12-15 2008-07-03 Lion Corp 液体口腔用組成物
JP2010043031A (ja) * 2008-08-13 2010-02-25 Lion Corp 液体口腔用組成物
WO2011055706A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
WO2011077847A1 (fr) * 2009-12-22 2011-06-30 ライオン株式会社 Composition liquide de type émulsion pour la cavité orale, et procédé de production de celle-ci
JP2012131769A (ja) * 2010-11-30 2012-07-12 Lion Corp 口腔用組成物
JP2013107837A (ja) * 2011-11-18 2013-06-06 Lion Corp 液体口腔用組成物及び液体口腔用組成物における変色抑制方法
US8829055B2 (en) 2006-03-23 2014-09-09 Kao Corporation Biofilm formation inhibitor composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083074A (ja) * 1994-06-21 1996-01-09 Sunstar Inc 口腔用液体組成物
JPH10212220A (ja) * 1997-01-30 1998-08-11 Lion Corp 口腔用組成物
JPH1112142A (ja) * 1997-06-19 1999-01-19 Lion Corp 口腔用組成物
JPH1112141A (ja) * 1997-06-25 1999-01-19 Lion Corp 口腔用組成物
JP2000319153A (ja) * 1999-05-13 2000-11-21 Lion Corp 口腔用組成物
JP2001172145A (ja) * 1999-12-15 2001-06-26 Lion Corp 口腔用組成物
JP2002012536A (ja) * 2000-06-27 2002-01-15 Lion Corp 口腔用組成物
JP2003292426A (ja) * 2002-01-29 2003-10-15 Lion Corp 歯磨剤組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083074A (ja) * 1994-06-21 1996-01-09 Sunstar Inc 口腔用液体組成物
JPH10212220A (ja) * 1997-01-30 1998-08-11 Lion Corp 口腔用組成物
JPH1112142A (ja) * 1997-06-19 1999-01-19 Lion Corp 口腔用組成物
JPH1112141A (ja) * 1997-06-25 1999-01-19 Lion Corp 口腔用組成物
JP2000319153A (ja) * 1999-05-13 2000-11-21 Lion Corp 口腔用組成物
JP2001172145A (ja) * 1999-12-15 2001-06-26 Lion Corp 口腔用組成物
JP2002012536A (ja) * 2000-06-27 2002-01-15 Lion Corp 口腔用組成物
JP2003292426A (ja) * 2002-01-29 2003-10-15 Lion Corp 歯磨剤組成物

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829055B2 (en) 2006-03-23 2014-09-09 Kao Corporation Biofilm formation inhibitor composition
JP2008100964A (ja) * 2006-10-20 2008-05-01 Kao Corp バイオフィルム生成抑制剤組成物
JP2008150305A (ja) * 2006-12-15 2008-07-03 Lion Corp 液体口腔用組成物
JP2010043031A (ja) * 2008-08-13 2010-02-25 Lion Corp 液体口腔用組成物
WO2011055706A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
JP2011098917A (ja) * 2009-11-06 2011-05-19 Lion Corp 歯磨剤組成物
WO2011077847A1 (fr) * 2009-12-22 2011-06-30 ライオン株式会社 Composition liquide de type émulsion pour la cavité orale, et procédé de production de celle-ci
CN102655844A (zh) * 2009-12-22 2012-09-05 狮王株式会社 乳化型液体口腔用组合物及其制造方法
JP2012131769A (ja) * 2010-11-30 2012-07-12 Lion Corp 口腔用組成物
JP2013107837A (ja) * 2011-11-18 2013-06-06 Lion Corp 液体口腔用組成物及び液体口腔用組成物における変色抑制方法

Also Published As

Publication number Publication date
JPWO2006067967A1 (ja) 2008-06-12
JP4873154B2 (ja) 2012-02-08

Similar Documents

Publication Publication Date Title
JP5136797B2 (ja) イソプロピルメチルフェノール含有液体口腔用組成物
JP4591680B2 (ja) 液体口腔用組成物
JP4957882B2 (ja) エタノール無配合洗口剤組成物
JP4985905B2 (ja) 液体口腔用組成物及びｌ−メントールの析出防止方法
JP5470837B2 (ja) 液体口腔用組成物
WO2006067967A1 (fr) Préparation liquide pour cavité orale
JP5729252B2 (ja) 口腔用組成物
JP5310553B2 (ja) 液体口腔用組成物、及びカチオン性殺菌剤の殺菌力向上方法
JP5359546B2 (ja) 液体口腔用組成物
JP2009256228A (ja) 液体口腔用組成物
JP5853387B2 (ja) 液体口腔用組成物及び該組成物へ成分を安定化配合する方法
JP5682283B2 (ja) 液体口腔用組成物
JP2010143843A (ja) 液体口腔用組成物
CN107205899B (zh) 液体口腔用组合物
JP4952940B2 (ja) 液体口腔用組成物
JP5051347B2 (ja) 液体口腔用組成物
JP5690744B2 (ja) 乳化型液体口腔用組成物及びその製造方法
JP6610001B2 (ja) 液体口腔用組成物
CN109689016B (zh) 液体口腔用组合物
JP2007197411A (ja) 液体口腔用組成物の製造方法
WO2023100804A1 (fr) Composition liquide à usage oral
JP2022096463A (ja) 液体口腔用組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006548784

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05814698

Country of ref document: EP

Kind code of ref document: A1